Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) shares gapped up before the market opened on Tuesday . The stock had previously closed at $30.29, but opened at $31.70. Supernus Pharmaceuticals shares last traded at $30.71, with a volume of 27,147 shares.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on SUPN. StockNews.com raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 17th. Cantor Fitzgerald restated a "neutral" rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.
View Our Latest Stock Report on SUPN
Supernus Pharmaceuticals Stock Performance
The firm has a market capitalization of $1.78 billion, a P/E ratio of 29.84 and a beta of 0.90. The stock has a fifty day moving average price of $32.09 and a two-hundred day moving average price of $34.97.
Insider Activity
In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Supernus Pharmaceuticals by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock worth $222,411,000 after acquiring an additional 22,852 shares during the period. Geode Capital Management LLC lifted its position in Supernus Pharmaceuticals by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock worth $54,633,000 after purchasing an additional 28,517 shares during the period. American Century Companies Inc. boosted its stake in Supernus Pharmaceuticals by 9.2% during the 4th quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock valued at $41,248,000 after purchasing an additional 95,777 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Supernus Pharmaceuticals by 5.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock valued at $27,242,000 after purchasing an additional 40,968 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Supernus Pharmaceuticals by 18.3% in the 4th quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company's stock worth $25,933,000 after buying an additional 110,867 shares in the last quarter.
About Supernus Pharmaceuticals
(
Get Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Recommended Stories
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
